AAV2-mediated gene transfer of GDNF to the striatum of MPTP monkeys enhances the survival and outgrowth of co-implanted fetal dopamine neurons

Experimental Neurology

Volumn 211, Issue 1, 2008, Pages 252-258

  Elsworth, J D ^a   Redmond Jr , D E ^a   Leranth, C ^a   Bjugstad, K B ^b   Sladek Jr , J R ^b   Collier, T J ^c   Foti, S B ^d   Samulski, R J ^d   Vives, K P ^a   Roth, R H ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Associated adenoviral vector (AAV); Dopamine; Fetal tissue; Glial derived neurotrophic factor (GDNF); Graft; Monkey; MPTP; Parkinson's disease; Striatum; Transplantation

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; PARVOVIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAUDATE NUCLEUS; CELL SURVIVAL; CELL TRANSPLANTATION; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; FETUS; GENE OVEREXPRESSION; GENE TRANSFER; IMMUNOHISTOCHEMISTRY; MALE; MESENCEPHALON; MONKEY; NERVE FIBER GROWTH; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL;

ANIMALS; CERCOPITHECUS AETHIOPS; CORPUS STRIATUM; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; DOPAMINE; EMBRYO, MAMMALIAN; FETAL TISSUE TRANSPLANTATION; GENE TRANSFER TECHNIQUES; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; MALE; MPTP POISONING; TIME FACTORS; TYROSINE 3-MONOOXYGENASE;

EID: 42749092092     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2008.01.026     Document Type: Article

References (58)

1. Ahn Y.H., Bensadoun J.C., Aebischer P., Zurn A.D., Seiger A., Bjorklund A., Lindvall O., Wahlberg L., Brundin P., and Kaminski Schierle G.S. Increased fiber outgrowth from xeno-transplanted human embryonic dopaminergic neurons with co-implants of polymer-encapsulated genetically modified cells releasing glial cell line-derived neurotrophic factor. Brain Res. Bull. 66 (2005) 135-142
2. Airaksinen M.S., and Saarma M. The GDNF family: signalling, biological functions and therapeutic value. Nat. Rev., Neurosci. 3 (2002) 383-394
3. Annett L.E. Functional studies of neural grafts in parkinsonian primates. In: Dunnett S.B., and Bjorklund A. (Eds). Functional Neural Transplantation (1994), Raven Press, New York
4. Bankiewicz K., Mandel R.J., and Sofroniew M.V. Trophism, transplantation, and animal models of Parkinson's disease. Exp. Neurol. 124 (1993) 140-149
5. Borgal L., Hong M., Sadi D., and Mendez I. Differential effects of glial cell line-derived neurotrophic factor on A9 and A10 dopamine neuron survival in vitro. Neuroscience 147 (2007) 712-719
6. Brundin P., Duan W.M., and Sauer H. Functional effects of mesencephalic dopamine neurons and adrenal chromaffin cells grafted to the rat striatum. In: Dunnett S.B., and Bjorklund A. (Eds). Functional Neural Transplantation (1994), Raven Press, New York 9-46
7. Brundin P., Karlsson J., Emgard M., Schierle G.S., Hansson O., Petersen A., and Castilho R.F. Improving the survival of grafted dopaminergic neurons: a review over current approaches. Cell Transplant 9 (2000) 179-195
8. Carlsson T., Winkler C., Lundblad M., Cenci M.A., Bjorklund A., and Kirik D. Graft placement and uneven pattern of reinnervation in the striatum is important for development of graft-induced dyskinesia. Neurobiol. Dis. 21 (2006) 657-668
9. Choi-Lundberg D.L., and Bohn M.C. Ontogeny and distribution of glial cell line-derived neurotrophic factor (GDNF) mRNA in rat. Brain Res. Dev. Brain Res. 85 (1995) 80-88
10. Doucet G., Brundin P., Descarries L., and Bjorklund A. Effect of prior dopamine denervation on survival and fiber outgrowth from intrastriatal fetal mesencephalic grafts. Eur. J. Neurosci. 2 (1990) 279-290
11. Elsworth J.D., Sladek Jr. J.R., Taylor J.R., Collier T.J., Redmond Jr. D.E., and Roth R.H. Early gestational mesencephalon grafts, but not later gestational mesencephalon, cerebellum or sham grafts, increase dopamine in caudate nucleus of MPTP-treated monkeys. Neuroscience 72 (1996) 477-484
12. Elsworth J.D., Taylor J.R., Sladek Jr. J.R., Collier T.J., Redmond Jr. D.E., and Roth R.H. Striatal dopaminergic correlates of stable parkinsonism and degree of recovery in old-world primates one year after MPTP treatment. Neuroscience 95 (2000) 399-408
13. Eslamboli A. Assessment of GDNF in primate models of Parkinson's disease: comparison with human studies. Rev. Neurosci. 16 (2005) 303-310
14. Espejo M., Cutillas B., Arenas T.E., and Ambrosio S. Increased survival of dopaminergic neurons in striatal grafts of fetal ventral mesencephalic cells exposed to neurotrophin-3 or glial cell line-derived neurotrophic factor. Cell Transplant 9 (2000) 45-53
15. Fine A., Hunt S.P., Oertel W.H., Nomoto M., Chong P.N., Bond A., Waters C., Temlett J.A., Annett L., Dunnett S., Jenner P., and Marsden C.D. Transplantation of embryonic marmoset dopaminergic neurons to the corpus striatum of marmosets rendered parkinsonian by 1-methyl-4-phenyl-1,2-3,6-tetrahydropyridine. Prog. Brain Res. 78 (1988) 479-489
16. Freed C.R., Breeze R.E., Rosenberg N.L., Schneck S.A., Kriek E., Qi J.X., Lone T., Zhang Y.B., Snyder J.A., Wells T.H., et al. Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease. N. Engl. J. Med. 327 (1992) 1549-1555
17. Freed C.R., Greene P.E., Breeze R.E., Tsai W.Y., DuMouchel W., Kao R., Dillon S., Winfield H., Culver S., Trojanowski J.Q., Eidelberg D., and Fahn S. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N. Engl. J. Med. 344 (2001) 710-719
18. Georgievska B., Carlsson T., Lacar B., Winkler C., and Kirik D. Dissociation between short-term increased graft survival and long-term functional improvements in Parkinsonian rats overexpressing glial cell line-derived neurotrophic factor. Eur. J. Neurosci. 20 (2004) 3121-3130
19. Georgievska B., Kirik D., and Bjorklund A. Overexpression of glial cell line-derived neurotrophic factor using a lentiviral vector induces time- and dose-dependent downregulation of tyrosine hydroxylase in the intact nigrostriatal dopamine system. J. Neurosci. 24 (2004) 6437-6445
20. Grieger J.C., and Samulski R.J. Adeno-associated virus as a gene therapy vector: vector development, production and clinical applications. Adv. Biochem. Eng. Biotechnol. 99 (2005) 119-145
21. Grieger J.C., Choi V.W., and Samulski R.J. Production and characterization of adeno-associated viral vectors. Nat. Protoc. 1 (2006) 1412-1428
22. Hagell P., and Cenci M.A. Dyskinesias and dopamine cell replacement in Parkinson's disease: a clinical perspective. Brain Res. Bull. 68 (2005) 4-15
23. Hagell P., Piccini P., Bjorklund A., Brundin P., Rehncrona S., Widner H., Crabb L., Pavese N., Oertel W.H., Quinn N., Brooks D.J., and Lindvall O. Dyskinesias following neural transplantation in Parkinson's disease. Nat. Neurosci. 5 (2002) 627-628
24. Hauser R.A., Freeman T.B., Snow B.J., Nauert M., Gauger L., Kordower J.H., and Olanow C.W. Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease. Arch. Neurol. 56 (1999) 179-187
25. Haycock J.W. Species differences in the expression of multiple tyrosine hydroxylase protein isoforms. J. Neurochem. 81 (2002) 947-953
26. Kirik D., Georgievska B., and Bjorklund A. Localized striatal delivery of GDNF as a treatment for Parkinson disease. Nat. Neurosci. 7 (2004) 105-110
27. Kordower J.H. In vivo gene delivery of glial cell line-derived neurotrophic factor for Parkinson's disease. Ann. Neurol. 53 Suppl 3 (2003) S120-S132 (discussion S132-124)
28. Lapchak P.A., Araujo D.M., Hilt D.C., Jiao S., Collin F., Miyoshi Y., Yi A., Zhang Z., and Gash D.M. Topographical distribution of [125I]-glial cell line-derived neurotrophic factor in unlesioned and MPTP-lesioned rhesus monkey brain following a bolus intraventricular injection. Brain Res. 789 (1998) 9-22
29. Lehmann I.T., Bobrovskaya L., Gordon S.L., Dunkley P.R., and Dickson P.W. Differential regulation of the human tyrosine hydroxylase isoforms via hierarchical phosphorylation. J. Biol. Chem. 281 (2006) 17644-17651
30. Lin L.F., Doherty D.H., Lile J.D., Bektesh S., and Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260 (1993) 1130-1132
31. Lindvall O., and Hagell P. Cell therapy and transplantation in Parkinson's disease. Clin. Chem. Lab. Med. 39 (2001) 356-361
32. McBride J.L., and Kordower J.H. Neuroprotection for Parkinson's disease using viral vector-mediated delivery of GDNF. Prog. Brain Res. 138 (2002) 421-432
33. Olanow C.W., Goetz C.G., Kordower J.H., Stoessl A.J., Sossi V., Brin M.F., Shannon K.M., Nauert G.M., Perl D.P., Godbold J., and Freeman T.B. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann. Neurol. 54 (2003) 403-414
34. Olanow C.W., Kordower J.H., and Freeman T.B. Fetal nigral transplantation as a therapy for Parkinson's disease. Trends Neurosci. 19 (1996) 102-109
35. Paterna J.C., Feldon J., and Bueler H. Transduction profiles of recombinant adeno-associated virus vectors derived from serotypes 2 and 5 in the nigrostriatal system of rats. J. Virol. 78 (2004) 6808-6817
36. Redmond Jr. D.E. Cellular replacement therapy for Parkinson's disease-where we are today?. Neuroscientist 8 (2002) 457-488
37. Redmond Jr. D.E., Sladek Jr. J.R., Roth R.H., Elsworth J.D., Collier T.J., Leranth C., Taylor J.R., Sortwell C.E., Bloch J., and Aebischer P. Restoring normal nigrostriatal anatomy in dopamine-depleted monkeys. Exp. Neurol. 175 (2002) 419
38. Rosenblad C., Martinez-Serrano A., and Bjorklund A. Glial cell line-derived neurotrophic factor increases survival, growth and function of intrastriatal fetal nigral dopaminergic grafts. Neuroscience 75 (1996) 979-985
39. Ruoslahti E. Brain extracellular matrix. Glycobiology 6 (1996) 489-492
40. Sautter J., Tseng J.L., Braguglia D., Aebischer P., Spenger C., Seiler R.W., Widmer H.R., and Zurn A.D. Implants of polymer-encapsulated genetically modified cells releasing glial cell line-derived neurotrophic factor improve survival, growth, and function of fetal dopaminergic grafts. Exp. Neurol. 149 (1998) 230-236
41. Schaar D.G., Sieber B.A., Dreyfus C.F., and Black I.B. Regional and cell-specific expression of GDNF in rat brain. Exp. Neurol. 124 (1993) 368-371
42. Sherer T.B., Fiske B.K., Svendsen C.N., Lang A.E., and Langston J.W. Crossroads in GDNF therapy for Parkinson's disease. Mov. Disord. 21 (2006) 136-141
43. Sinclair S.R., Svendsen C.N., Torres E.M., Martin D., Fawcett J.W., and Dunnett S.B. GDNF enhances dopaminergic cell survival and fibre outgrowth in embryonic nigral grafts. NeuroReport 7 (1996) 2547-2552
44. Sladek Jr. J.R., Elsworth J.D., Taylor J.R., Roth R.H., and Redmond Jr. D.E. Techniques for neural transplantation in non-human primates. In: Ricordi C., and Landes R.G. (Eds). Techniques for Neural Transplantation (1995), CRC Press, Austin 391-408
45. Sondhi D., Peterson D.A., Giannaris E.L., Sanders C.T., Mendez B.S., De B., Rostkowski A.B., Blanchard B., Bjugstad K., Sladek Jr. J.R., Redmond Jr. D.E., Leopold P.L., Kaminsky S.M., Hackett N.R., and Crystal R.G. AAV2-mediated CLN2 gene transfer to rodent and non-human primate brain results in long-term TPP-I expression compatible with therapy for LINCL. Gene Ther. 12 (2005) 1618-1632
46. Spencer D.D., Robbins R.J., Naftolin F., Marek K.L., Vollmer T., Leranth C., Roth R.H., Price L.H., Gjedde A., Bunney B.S., et al. Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson's disease. N. Engl. J. Med. 327 (1992) 1541-1548
47. Steece-Collier K., Collier T.J., Danielson P.D., Kurlan R., Yurek D.M., and Sladek Jr. J.R. Embryonic mesencephalic grafts increase levodopa-induced forelimb hyperkinesia in parkinsonian rats. Mov. Disord. 18 (2003) 1442-1454
48. Stromberg I., Bjorklund L., Johansson M., Tomac A., Collins F., Olson L., Hoffer B., and Humpel C. Glial cell line-derived neurotrophic factor is expressed in the developing but not adult striatum and stimulates developing dopamine neurons in vivo. Exp. Neurol. 124 (1993) 401-412
49. Sullivan A.M., Pohl J., and Blunt S.B. Growth/differentiation factor 5 and glial cell line-derived neurotrophic factor enhance survival and function of dopaminergic grafts in a rat model of Parkinson's disease. Eur. J. Neurosci. 10 (1998) 3681-3688
50. Taylor J.R., Elsworth J.D., Roth R.H., Sladek Jr. J.R., Collier T.J., and Redmond Jr. D.E. Grafting of fetal substantia nigra to striatum reverses behavioral deficits induced by MPTP in primates: a comparison with other types of grafts as controls. Exp. Brain Res. 85 (1991) 335-348
51. Taylor J.R., Elsworth J.D., Roth R.H., Sladek Jr. J.R., and Redmond Jr. D.E. Behavioral effects of MPTP administration in the vervet monkey: a primate model of Parkinson's disease. In: Woodruff M.L., and Nonneman A.J. (Eds). Toxin-Induced Models of Neurological Disorders (1994), Plenum Press, New York 139-174
52. Taylor J.R., Elsworth J.D., Roth R.H., Sladek Jr. J.R., and Redmond Jr. D.E. Severe long-term 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the vervet monkey (Cercopithecus aethiops sabaeus). Neuroscience 81 (1997) 745-755
53. Taymans J.M., Vandenberghe L.H., Haute C.V., Thiry I., Deroose C.M., Mortelmans L., Wilson J.M., Debyser Z., and Baekelandt V. Comparative analysis of adeno-associated viral vector serotypes 1, 2, 5, 7, and 8 in mouse brain. Hum. Gene Ther. 18 (2007) 195-206
54. Tenenbaum L., Chtarto A., Lehtonen E., Velu T., Brotchi J., and Levivier M. Recombinant AAV-mediated gene delivery to the central nervous system. J. Gene Med. 6 Suppl 1 (2004) S212-S222
55. Venstrom K.A., and Reichardt L.F. Extracellular matrix. 2: role of extracellular matrix molecules and their receptors in the nervous system. FASEB J. 7 (1993) 996-1003
56. Widner H., Tetrud J., Rehncrona S., Snow B., Brundin P., Gustavii B., Bjorklund A., Lindvall O., and Langston J.W. Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). N. Engl. J. Med. 327 (1992) 1556-1563
57. Wilby M.J., Sinclair S.R., Muir E.M., Zietlow R., Adcock K.H., Horellou P., Rogers J.H., Dunnett S.B., and Fawcett J.W. A glial cell line-derived neurotrophic factor-secreting clone of the Schwann cell line SCTM41 enhances survival and fiber outgrowth from embryonic nigral neurons grafted to the striatum and to the lesioned substantia nigra. J. Neurosci. 19 (1999) 2301-2312
58. Yurek D.M. Glial cell line-derived neurotrophic factor improves survival of dopaminergic neurons in transplants of fetal ventral mesencephalic tissue. Exp. Neurol. 153 (1998) 195-202